Scholars Central

Conference abstract

Targeted molecular therapy versus targeted drug delivery for hematological cancers

Authors: Michael A Firer

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Recent years have seen significant developments in the treatment of several types of hematological cancers and in some settings, this has translated into improved clinical outcome. Arguably, the most dramatic of these improvements has been seen in the treatment of multiple myeloma. These developments have mostly been guided by advances in our understanding of the underlying biology and pathogenicity of these diseases. These advances have for example highlighted a series of driver mutations in key components of cellular signaling pathways that provide molecular targets for novel small molecule drugs. Parallel developments in gene and protein profiling technologies are beginning to allow the tailored employment of these drugs in personalized treatment protocols. Nonetheless, this approach has limitations, possibly the most important being the genetic instability of the tumor and the development of drug resistance. An alternate approach to improved cancer therapy is the use of targeted drug delivery systems. These are, in the first instance, reliant on the ability to identify a unique tumor cell surface component, for use as a specific ?address? to deliver the drug. This approach has advantages in terms of target cell specificity and bypassing drug resistance pathways. This paper will first describe the advantages and limitations of both targeted molecular therapy and targeted drug delivery approaches and then make suggestions to amalgamate the two systems. Finally, the talk will present an update on our work to develop targeted drug delivery systems for Chronic Lymphocytic Leukemia and Multiple Myeloma.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Blood Disorders & Transfusion.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Michael A Firer”